secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001213900-25-028622
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology amends license agreement with Eisai, defers $8.2M in LYMPHIR payments to 2025
--------------------------------------------------------------------------------

- Total obligations owed to Eisai: $8,233,209.77 including $5.9M milestone and $2.33M development/inventory costs.
- Payment schedule: $2,535,317.77 by July 15, 2025; four monthly $2.35M payments; final $2,197,892.07 by Dec 15, 2025.
- Interest at 2% per annum on delayed amounts from original due dates.
- Parties released each other from claims related to late payment of milestone and other costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025028622/0001213900-25-028622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025028622/ea0237093-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-028622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer